Leading Edge Pharms names chief science officer
Leading Edge Pharms, a biotech company focused on cannabinoid therapies and new delivery systems, has named a head of its scientific efforts. The Henderson, Nev.-based company has appointed Daniel Holsworth as its chief science officer.
“One of our key differentiators has always been a commitment to clinical thoroughness, even as many CBD products are being rushed to market to capitalize on a new trend,” said David Chadwick, CEO of Leading Edge Pharms. “Dan has been an important part of the LEP team for two years as a consultant and was instrumental in the development of Silvidiol, our liposomal CBD compound and delivery system. Now, as CSO, Dan will lead our research and development efforts and be directly responsible for the formulation of many exciting new products LEP will be releasing in 2019. We look forward to working closely together to advance the scientific work being done within the cannabis industry.”
Holsworth has more than 25 years of experience in drug discovery and development, entrepreneurship, and regulatory affairs. His previous roles include technical advisor at CA Botana International, co-founder and head of chemistry at Odin Therapeutics and associate research fellow medicinal chemist at Pfizer. At CA Botana International, he worked to formulate therapeutic skin care products using stem cell development pathway biology and peptide chemistry. He holds 25 patents for his discoveries, Leading Edge Pharms said.
“Pharmaceuticals addressing pain often have unfortunate side effects and can even be addictive. Additionally, these drugs unnecessarily impact the entire body, rather than targeting specific pain sites,” Holsworth said. “CBD is a natural pain reliever and can be used effectively to target peripheral neuropathic pain at the nerve level where pain occurs,” Holsworth said. “Our vision at LEP is to bring CBD treatments into mainstream clinical practice as a first step in pain management. There are other natural and effective solutions available, and patients should be aware of their options.”
No comments found